Dupilumab

Limits on what this shows

• Why no grade: Both conditions of Step 7 hold: no Tier B or C evidence supports even a yellow grade, and no circulating consumer claim about dupilumab and mitochondria was found. The serum TCA-intermediate shift [8] is counted only in the ATP entry and is not mitochondrial structure or function data.

Channels tried

WebSearch "dupilumab mitochondria OR mitochondrial dysfunction OR oxidative phosphorylation IL-4 receptor" and "dupilumab mitochondrial function OR mitochondrial respiration OR ATP keratinocytes OR T cells": results were disease-level mitochondrial reviews, an ERS abstract on mepolizumab and prednisolone (a different drug, not read) and a keratinocyte media product listing; none measured mitochondria on dupilumab. A PubMed mitochondria listing was blocked by rate limits (429) on the original pass. On the repair pass WebSearch was unavailable (shared budget exhausted) and no new mitochondria-specific PubMed query could be completed; the only adjacent dupilumab source remains the serum metabolomics study [8], whose full text states no mitochondrial measurement (the TCA cycle is mentioned only as background to the matrix location).

Gap type

Likely a genuine literature gap, with a tooling limit: the PubMed listing for this category could not be completed on either pass and WebSearch was exhausted on the repair pass.

Limits on what this shows

• Null findings: None located. No study found that measured a redox marker on dupilumab and saw it rise.
• At-risk subgroups: None identified.

Regulatory status

Not mentioned in the label sections read [1][2].

Population evidence

Raimondo 2023 [7]: 25 adults with moderate-to-severe atopic dermatitis who were candidates for dupilumab and 15 matched healthy controls. Urine sampled before treatment and at 8, 16 and 52 weeks and 2 years; biopyrrins by ELISA. Levels were higher in atopic dermatitis than in controls, correlated with EASI, total IgE and CRP, and fell at 8 and 16 weeks with the reduction maintained at 52 weeks and 2 years. Effect size, CI and p values were not retrievable: four records of the abstract (two PubMed single-record fetches on separate days, an OpenAlex works/pmid reconstruction and the Salerno institutional repository page) all give no concentrations, and the Minerva Medica article page returned a fetch error on the repair attempt. Abstract-level read; the only quantitative content is n = 25 and n = 15. A serum metabolomics study [8] (33 patients, 16 weeks) reports in its discussion that the authors suggest dupilumab "may attenuate oxidative stress-mediated inflammation", which is interpretation, not a measured redox result.

Mechanism

Indirect. Dupilumab is a protein with no antioxidant chemistry of its own. Blocking IL-4 and IL-13 signaling lowers type 2 inflammation, and inflammatory-cell reactive oxygen output is a plausible downstream correlate. Not shown directly.

Counter-evidence held on record

Counter-evidence and confounding Single arm before and after, no untreated atopic dermatitis comparison. The marker tracks EASI and CRP, so it may be reporting inflammation resolving rather than a drug redox effect. A single marker (urinary biopyrrin) is not a validated panel of oxidative stress. Framing caution This is a reverse-direction, disease-linked finding. It is not a deficiency claim and gives no basis for antioxidant supplementation.

Limits on what this shows

• Null findings: No dupilumab-specific iron study located. A PubMed listing for dupilumab with ferritin, hepcidin or iron deficiency returned a single pediatric case report [16].
• At-risk subgroups: People with atopic dermatitis and active inflammation, and children with eosinophilic gastrointestinal disease with bleeding (indication-linked, not drug-linked).

Regulatory status

Not mentioned in the label sections read. The label lists helminth infections in pediatric asthma (6 subjects, 2.2%, versus 1, 0.7%; enterobiasis and ascariasis) [1], with no iron link stated.

Population evidence

Nutrients 2025 [15]: cross-sectional, 86 adults with moderate-to-severe atopic dermatitis (85 complete cases), biologic- and JAK-naive. Ferritin under 30 ug/L in 32 (37%), transferrin saturation under 20% in 39 (45%), anemia 13 (15%), inflammation-adjusted iron deficiency 67 of 86 (78%). Dupilumab was not in this cohort and the authors did not assess therapy effects, so this is disease context, not a drug finding (Hard Rule 6). Case report [16]: a girl with collagenous gastritis and iron deficiency anemia from age 4.5 who needed repeated IV iron; hemoglobin and ferritin normalized on prednisone and stayed normal for 15 months on dupilumab without iron; no numeric values in the abstract. Steroid exposure confounds it. In the adult extension, low hemoglobin incidence did not rise over time [6].

Mechanism

Absent. Dupilumab has no chelation, gastric-pH, catabolic or iron-transport mechanism [2]. Iron indices in atopic dermatitis are linked to inflammation and severity in the context cohort [15].

Counter-evidence held on record

Counter-evidence and confounding Confounding by indication is presumed. Baseline deficiency in untreated atopic dermatitis is already high [15], so a low ferritin on dupilumab does not implicate the drug. Framing caution Indication-linked context, not a depletion claim. Iron repletion should follow measured deficiency under clinician guidance, not this entry.

Limits on what this shows

• Why no grade: No Tier B or C evidence and no circulating claim for copper and dupilumab. Both Step 7 conditions hold. This is not a finding of safety.

Channels tried

WebSearch "dupilumab serum copper OR zinc OR ceruloplasmin atopic dermatitis": returned zinc and copper status studies in children with asthma and atopic dermatitis (disease-level; titles seen, not opened) and no dupilumab data. PubMed listing "dupilumab AND (copper OR ceruloplasmin OR zinc OR selenium)": 3 unrelated records (eyebrow madarosis review, Swiss prurigo recommendations, Zn(II) extraction in biologic drug products). A follow-up WebSearch "dupilumab copper" was refused because the shared search budget was used up. Repair pass: WebSearch again refused (budget exhausted); PubMed listings for dupilumab with copper, ceruloplasmin or trace elements returned fetch errors on two phrasings and a 429 on a third; an OpenAlex works search returned 429. The label and monograph do not mention copper [1][2].

Gap type

Probable genuine literature gap on the channels that worked in the original pass (one PubMed listing returned 3 unrelated records), but the repair pass could not re-run listings: tooling-limited, so a later revision should repeat the PubMed and OpenAlex searches when access recovers.

Limits on what this shows

• Null findings: Esophageal microbiome studies in eosinophilic esophagitis [13][14] covered diet, PPI and swallowed steroid therapy and did not include dupilumab, so they are context only and were not borrowed.
• At-risk subgroups: None identified.

Regulatory status

Not mentioned in the label sections read [1][2].

Population evidence

PRISM, Yie 2026 [9]: 48 adults with severe asthma, all on dupilumab; stool bacteria, stool extracellular vesicles and exhaled breath condensate profiled by sequencing, with responder versus non-responder and over-time comparisons. Responders had lower Lachnospira in stool bacteria (q = 0.046) and vesicles (q = 0.042), lower Escherichia-Shigella in vesicles (q = 0.038), and higher Oscillospiraceae NK4A214 in both (q = 5.5 x 10^-7 and 1.4 x 10^-8); stool richness showed a time-dependent association with blood eosinophils (p for interaction = 0.023), and breath-condensate diversity tracked baseline sputum eosinophils (p = 0.018). These q values come from the OpenAlex-reconstructed abstract; relative-abundance magnitudes, responder counts and confidence intervals are not in the abstract, and the article is closed access (full text not opened). No untreated comparator arm, so the contrasts are responder versus non-responder, not dupilumab versus non-use. Zhang 2026 [10]: pilot longitudinal study of skin and gut microbiomes in children with moderate-to-severe atopic dermatitis on dupilumab; only a two-line summary ("coordinated microbiome remodelling with divergent bacterial and fungal responses"; "gut-skin crosstalk") could be retrieved because Crossref and OpenAlex carry no abstract and the PubMed record has none. No sample size or taxa could be read. Other sites, not gut and not graded here: skin (30 adults, Staphylococcus 44.3% to 11.8%, S. aureus qPCR down 94.1%, Shannon diversity up) [11] and saliva (15 patients, 6 on dupilumab, Actinomycetota 11.87% to 6.15%, q = 0.0094) [12].

Mechanism

Plausible but untested. IL-4 and IL-13 shape epithelial and mucosal immune function, so type 2 blockade could change gut communities; no source here tests that pathway.

Counter-evidence held on record

Counter-evidence and confounding Both gut studies are small, uncontrolled for non-use and report treatment-response associations. The skin findings run in the favorable direction (less S. aureus) and the oral shifts are of unclear meaning. Disease improvement and concurrent therapy confound any shift. Framing caution This is not a depletion or harm claim. The gut data describe differences between responders and non-responders; they do not show dupilumab damaging the gut microbiome.

Limits on what this shows

• Null findings: None located measuring ATP, respiration or membrane potential on dupilumab.
• At-risk subgroups: None identified.

Regulatory status

Not mentioned in the label sections read [1][2].

Population evidence

Front Immunol 2022 [8]: serum metabolomics and lipidomics before and after 16 weeks of dupilumab in 33 patients with atopic dermatitis (19 well responders, 14 poor responders). Differential metabolites enriched the citrate cycle, branched-chain amino acid biosynthesis, glycerophospholipid, arachidonic acid, sphingolipid and pyrimidine pathways, more in well responders. From the full text: citrate, succinate and malate were reduced; fructose 2,6-bisphosphate was raised; branched-chain amino acids were higher after treatment. Forty-one metabolites and 218 lipids met the VIP > 1, p < 0.05 criteria (Supplementary Table S2); fold changes and p values for citrate, succinate and malate sit in that table, which could not be retrieved (the Frontiers page carries only placeholder anchors, the article PDF does not reproduce it, and the Europe PMC supplementary-file listing returned 429). The authors state the TCA and BCAA interpretations are speculative and suggest dupilumab "may ... promote energy metabolism".

Mechanism

Absent as a direct mitochondrial mechanism. Dupilumab binds a cell-surface receptor. Lower serum TCA intermediates could reflect altered cellular demand as inflammation resolves; this is not demonstrated.

Counter-evidence held on record

Counter-evidence and confounding Serum intermediate levels do not equal cellular ATP output. Self-controlled design, no external validation, small sample, and response status confounds every pathway. Shared origin with the oxidative-stress entry's speculation is disclosed in the overlap map. Framing caution Not an energy-deficit claim. No fatigue or low-energy statement should be derived from this entry.

Limits on what this shows

• Null findings: Mean hematology unchanged over 16 weeks and up to 5 years [5][6].
• At-risk subgroups: None established. Anemia in a case report was bleeding-driven, not a red-cell production deficit [18].

Regulatory status

No anemia or hemoglobin warning in the label sections read [1]. The label warns of eosinophilic conditions (pneumonia, EGPA) [1].

Population evidence

Adolescent RCT lab analysis [5]: LIBERTY AD ADOL, 251 randomized and 250 analyzed, 16 weeks. Red cell, white cell and platelet parameters were assessed; the authors conclude no routine lab monitoring is required; platelet means fell by 8.1 (placebo), 17.6 (q2w) and 15.4 (q4w) x 10^9/L with no grade 2 or higher drops; hemoglobin was not named in the page read, which says red blood cell parameters were similar between arms at baseline and showed no clinically meaningful shifts, with grade 1 to 3 anemia proportions and the red-cell values held in electronic supplement Tables S2a and S2b that the publisher host disallows fetching. Adult open-label extension [6]: 2,677 adults entered, up to 5 years; no clinically meaningful change in mean hematology or chemistry; grade 1 and 2 low hemoglobin incidence declined from week 4 to end of study (Table 5 not read; a second Springer fetch on the repair pass returned 429 and was not retried); one serious hemolytic anemia in one patient, reported as not related to the study drug and resolved; one dupilumab-naive patient had grade 3 low hemoglobin. Case-level (Tier B): acquired hemophilia A with bleeding, hemoglobin 15.0 g/dL to 7.2 g/dL, recovered on prednisone [18]; an immune thrombocytopenic purpura case (abstract missing) [19]. Retrospective Italian cohort of 139 patients with hematologic comorbidities: 82.7% stable, 16.6% resolved, 0.7% progressed; no hemoglobin values reported [17].

Mechanism

Absent for oxygen carrying capacity: no hemolytic, methemoglobin-forming or marrow-suppressing mechanism is described. The rare cases are consistent with immune dysregulation and are unproven as drug effects.

Counter-evidence held on record

Counter-evidence and confounding Case reports cannot establish causation and the investigator in the extension judged the hemolytic anemia unrelated. Anemia is not iron deficiency and a bleeding or autoimmune event is not a nutrient finding. Framing caution Not a deficiency claim. Unexplained fatigue, pallor or bruising on dupilumab is a prompt for a clinician-ordered blood count, not for supplements.